| Bioactivity | NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis[1][2]. |
| Target | CD47/SIRPα axis |
| Name | NCGC00138783 free base |
| CAS | 896700-07-5 |
| Formula | C26H26FN7OS |
| Molar Mass | 503.59 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Junqiao Zhu, et al. CD47-SIRPα axis in cancer therapy: Precise delivery of CD47-targeted therapeutics and design of anti-phagocytic drug delivery systems. Medicine in Drug Discovery. 2022. 15:100139 [2]. Bo Huang, et al. Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy. Comput Struct Biotechnol J. 2021 Oct 1;19:5494-5503. |
NCGC00138783 free base
CAS: 896700-07-5 F: C26H26FN7OS W: 503.59
NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free ba
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.